New drug mimics natural protein to calm overactive immune system in nerve disease
NCT ID NCT07027111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve function. Researchers are checking how safe it is and whether it helps patients feel better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NVG-2089 (a drug designed to mimic IVIg protein to calm the immune system)
- What this could lead to
- If it works, this could provide a new treatment option for people with CIDP, potentially reducing nerve damage and improving daily function.
- What could go wrong
- This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nuvig Site
Denton, Texas, 76208, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody calm the immune attack in CIDP?
- Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
- Shocking muscles to move: new exercise hope for nerve disease patients
- Could a stem cell transplant stop the immune system from attacking the brain?
- Engineered immune cells take on multiple sclerosis and other nerve diseases
- New drug IMVT-1402 aims to stop CIDP relapses in Mid-Stage trial